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Abstract
Background: To enhance myocardial angiogenic gene expression, a novel gene delivery strategy was tested.
Direct intramyocardial injection of an angiogenic gene with microbubbles and insonation were applied in a dog
animal model. Dogs received one of the four different treatments in conjunction with either the enhanced green
fluorescence protein (EGFP) gene or the hepatocyte growth factor (HGF) gene: gene with microbubbles (MB) and
ultrasound (US); gene with US; gene with MB; or the gene alone.
Results: Distribution of MB and the gene in the myocardium was visualized during the experiment. Compared
with the EGFP gene group, an average 14.7-fold enhancement in gene expression was achieved in the EGFP+MB/
US group (P < 0.01). Compared with the HGF gene group, an average 10.7-fold enhancement in gene expression
was achieved in the HGF+MB/US group (P < 0.01). In addition, capillary density increased from 20.8 ± 3.4/mm2 in
the HGF gene group to 146.7 ± 31.4/mm2 in HGF+MB/US group (P < 0.01).
Conclusions: Thus, direct intramyocardial injection of an angiogenic gene in conjunction with microbubbles plus
insonation synergistically enhances angiogenesis. This method offers an observable gene delivery procedure with
enhanced expression efficiency of the delivered gene.
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Background
Recently, delivering biological agents to areas of the myo-
cardium to treat cardiovascular disease has attracted
much attention [1]. The delivery of angiogenic genes to
the myocardium is one such approach. For example,
angiogenesis was reported to occur with direct intramyo-
cardial injection of a plasmid vector during open-heart
surgery in patients [2]. However, compared with viral
vectors, the gene expression for intramyocardial injection
of nonviral vectors is less efficient. Hepatocyte growth
factor (HGF) acts as a potent cell growth factor and pro-
motes angiogenesis of the infracted myocardium [3,4].
Thus, HGF could improve angiogenesis in the chronically
ischemic myocardium, which indicates a potent therapeu-
tic value of HGF gene transfection for treating chronic
ischemic heart diseases [5,6]. Real-time magnetic reso-
nance imaging has been used to monitor the delivery of
therapeutic reagents to the myocardium. However, its
clinical application is limited by its potential side effects
and complications [7]. Therefore, an effective and safe
delivery strategy is needed to enhance therapeutic angio-
genic responses in ischemic myocardium.
Recently, some studies have showed that microbubbles
can be mixed with DNA and then be delivered to tar-
geted areas [8-10]. Microbubbles (MBs) can lower the
energy threshold of US for cavitation, which transiently
perforates the cell membrane or disrupts the capillary
wall to allow delivery of bioactive agents into cells
or the interstitial space; many studies of microbubble
applications combined with insonation in rodents are
emerging [11-17]. Whether regional application of an
angiogenic gene and microbubbles combined with ultra-
sound in bigger animals would enhance gene expression
and angiogenesis is not known. Moreover, microbubbles
may be also used as an imaging marker to show the dis-
tribution of the therapeutic agents mixed with micro-
bubbles in the myocardium. Therefore, it is of interest
to further investigate the regional application of micro-
bubbles in larger animals.
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EGFP has been widely used as a reporter gene [18]. In
the first part of this study, we tested the feasibility of
direct intramyocardial delivery of the EGFP gene and
microbubbles to enhance gene expression by measuring
the EGFP expression in the normal myocardium of
dogs. We next evaluated the gene expression and the
angiogenic effects of direct intramyocardial delivery of a
mixture of a low-dose of the HGF gene and microbub-
bles combined with insonation in dogs with induced
myocardial infarction. We found this technique to be a
promising, visible, and effective intramyocardial gene
delivery system.
Materials and methods
Animal procedures
Male adult hybrid dogs (12-15 kg) from the Laboratory
Animal Center of Chongqing University of Medical
Science were used in this study. All experimental proce-
dures conformed to the Guide for the Care and Use of
Laboratory Animals published by the US National Insti-
tutes of Health (NIH publication 85-23, revised 1996).
Sixteen dogs were randomly divided into four groups (n
= 4) to receive the following treatments: (1) EGFP,
microbubbles, and ultrasound (EGFP+MB/US group);
(2) EGFP and ultrasound (EGFP+US group); (3) EGFP
and microbubbles (EGFP+MB group), and (4) EGFP
alone. Acute myocardial infarction was induced in
another 36 dogs, which then were divided into six
groups of six animals and treated with HGF+MB/US,
HGF+US, HGF+MB, HGF alone, MB/US, or surgery
alone (control). All procedures on animals were
approved by the Institutional Animal Care and Use
Committee at Chongqing University of Medical Science.
Preparation of microbubbles
Microbubbles were prepared at the Institute of Ultra-
sound Imaging at Chongqing Medical University as
described by Li et al. (2008) [12]. The mean diameter
and concentration of the microbubbles were measured
using a Coulter counter (Coulter Electronics, Hialeah,
FL, USA). The microbubble solution was sterilized by
60Co irradiation. The quantified plasmids (pEGFP) then
were added and mixed gently with the microbubbles.
The microbubble solution was then diluted with saline
to a final concentration of 1.42 ± 0.26 ×109/ml before
intramyocardial injection. The diameter range of the
self-made lipid microbubble was 2.11 to 6.43 μm; the
mean diameter was 2.79 μm.
Plasmid purification
Plasmid DNA was produced according to a standard
method (TaKaRa Biotechnology, Tokyo, Japan) and pur-
ified to remove endotoxin contamination. The plasmids
pEGFP-N2 and pcDNA3.0-HGF were kindly provided
by Dr. Zuo YL and Li XS of Chongqing University of
Medical Science, China. The plasmid contained the
EGFP -N2 cDNA that uses a CMV promoter to drive
EGFP expression, we used a naked HGF plasmid
(AnGes MG Inc., Tokyo, Japan), which contained the
human HGF complementary DNA (2.2kb) that uses the
cytomegalovirus promoter/enhancer to drive HGF
expression. Purified plasmid DNA was dissolved in ster-
ile water and stored at -20°C.
Plasmid pEGFP transfer
After an abdominal cavity injection of sodium pentobar-
bital (15 mg/kg), the heart of each of the 16 dogs in the
EGFP experiment was exposed by median sternotomy.
For the dogs in the EGFP+US/MS group and the EGFP
+MB group, 500 μg of total plasmid DNA in 0.5 ml of
microbubble solution were injected intramuscularly at
the left anterior free wall at five separate sites. For the
ultrasound treatment, an ultrasound transducer then
was placed on the heart separated by a 2 mm ultrasonic
coupling agent. In the EGFP+MB/US group, continuous
insonation was provided using an ultrasound gene trans-
fection treatment meter [UGT]-1025 (Institute of Ultra-
sound Imaging of Chongqing Medical University,
Chongqing, PR China) under the following conditions:
30 s with a 10 s pause, 1 MHz, 1 W/cm2, 60 s in total
at each site [19]. In the EGFP+US group, the same
amount of the EGFP gene without MB was injected into
the myocardium, followed by the same insonation pro-
cedure. Only the gene was injected into the myocardium
in the EGFP group without MB and US. An electrocar-
diogram was continuously monitored during the pro-
cess. After these procedures, the animals were allowed
to recover.
Production of acute myocardial infarction
The remaining 36 dogs were used to generate the myocar-
dial infarction model. They were intraperitoneally anesthe-
tized with sodium pentobarbital (15 mg/kg), then
intubated and ventilated with a volume-cycled small-ani-
mal ventilator. An anterior thoracotomy was performed to
open the pericardium. The heart was then rapidly exterior-
ized, and a 4-0 silk suture was tightened around the proxi-
mal left anterior descending coronary artery (before the
second branch of the diagonal artery). Visible epicardial
feeders at the margins of the occluded bed were ligated to
decrease the collateral and produce transmural injury [20].
Aqueous penicillin G (200 000U/Kg) was given the day
of, and the day after surgery as prophylaxis against
wound infection. The incision remained dry for all dogs.
The dogs were provided an appropriate environment
including a clean and warm shelter and a comfortable
resting area, ready access to fresh water and a diet
to maintain full health and vigour. Zubrin tablets
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(Tepoxalin, 100 mg tablets, Schering-Plough Animal
Health Corp) were administered in moist food for five
days. Dogs received 20 mg/kg once a day on the initial
day of treatment followed by a daily maintenance dose of
10 mg/kg once a day. We found that the dogs’ average
recovery to normal activity was five days after surgery.
The dogs were divided into the following six treatment
groups after the models of myocardial infarction were
prepared (n = 6): (1) HGF+MB/US; (2) HGF+US; (3)
HGF+MB; (4) HGF alone; (5) MB/US; and (6) surgery
alone (control).
Plasmid pcDNA3.0-HGF transfer
Five minutes after the coronary artery was tightened,
500 μg of total plasmid DNA in 0.5 ml of lipid micro-
bubble solution were injected along the left ventricular
free wall at five separate sites in the dogs in the HGF
+MB/US group and the HGF+MB group. Then, contin-
uous insonation was administered via an ultrasound
gene transfection treatment meter [UGT]-1025 for 30 s
with a 10s pause at 1-MHz and 1-W/cm2 for 60s in
total at each site in the HGF+MB/US group [19]. In the
HGF+US group, the HGF gene was injected into the
myocardium, followed by the same insonation proce-
dure. In the MB/US group, the MB was injected into
the myocardium, followed by the same insonation pro-
cedure. In the HGF alone group, only the gene was
injected. In the control group, 0.5 ml of saline was
injected into the myocardium. An electrocardiogram
was continuously monitored during the process. After
these procedures, the animals were allowed to recover.
Analysis of regional microbubble imaging
After intramyocardial injection of a mixture of 100 μg of
pEGFP and 0.1 ml of microbubble solution, ultrasonic
gel (Aquasonics 100; Parker Labs, USA) was adminis-
tered around the injection site of three new dogs; trans-
thoracic diagnostic echocardiography (a Sonos 4500
ultrasound system and a 3 MHz linear array transducer,
Philips Inc., USA) was used to measure the area of
microbubbles existence in the regional myocardium at
the time points 0, 5, 10, 20, 30, 40, 50, and 60 min.
Histopathological examination and analysis of creatine
kinase (CK)
The 16 dogs in the EGFP experiment were deeply anesthe-
tized with pentobarbital at 48 h, and the heart was rapidly
excised. After removal of the atrium and the right
ventricle, the left ventricle was opened and examined to
determine the gross appearance of the specimen. Cross-
sectional surfaces at the injection sites were also inspected
for intramural hematomas. Following macroscopic exami-
nation, the hearts were transversally sliced. Part of the
myocardium was fixed in formalin. Paraffin-embedded
myocardium was cut into 5-7 μm thick slices. CK secre-
tion was measured to test for myocardial damage using a
Hitachi 7170A automatic biochemistry analyzer (Japan).
CK secretion was measured before the experiment, during
the operation, at the end of the experiment, and at 24h
and 48 h after transfection in the four EGFP groups.
Evaluation of EGFP gene expression
EGFP gene expression was assessed at 48 h after trans-
fection. EGFP mRNA levels were monitored by RT-PCR
using a two-step RT-PCR kit (AMV, TaKaRa, Japan) on
a PCR system (MyCycler, BioRad). Sequences of primers
for EGFP were: 5’- GCC ACA AGT TCA GCG TGT C
-3’ (sense), 5’- TCA CCT TGA TGC CGT TCT T -3’
(antisense), and RT-PCR was performed under the fol-
lowing conditions: an initial heating to 94°C for 2 min;
then 94°C for 30 s, 55°C for 40 s, 72°C for 40 s for 38
cycles; and then 72°C for 5 min. The products were
separated by gel electrophoresis. All electrophoresis
blots were quantified using Quantity One software
(BioRad).
Evaluation of EGFP protein expression
EGFP protein expression was assessed using a laser
scanning confocal fluorescence microscope (Carl Zeiss
LSM510, Axiovert 100 M, Jena, Germany). After the
dogs were sacrificed, the heart was excised and placed
in optimum cutting temperature compound and shock
frozen prior to storage at -20°C. The fluorescence was
visualized at 488nm excitation wavelengths using a con-
focal laser scanning fluorescence microscope (Carl Zeiss
LSM510, Axiovert 100 M, Jena, Germany). Each sample
measurement was repeated eight to ten times.
Evaluation of HGF gene expression
HGF gene expression was assessed at day 28 after trans-
fection. The expression of HGF was assessed using com-
mercially available ELISA kits (Duoset HGF ELISA DY-
294; R&D Systems Inc., USA) following the protocols
recommended by the manufacturer. Briefly, enzyme-
linked polyclonal antibodies specific for HGF protein
were added to the wells, and the intensity of the color
was measured and compared with a standard curve.
Evaluation of capillary density
Paraffin-embedded myocardium was cut into 3-4 μm
thick slices. Specimens were incubated with polyclonal
rabbit anti-dog CD31 antibody (platelet endothelial cell
adhesion molecule 1; bs-0468R, Beijing Biosynthesis Bio-
technology Co. Ltd., Beijing, PR China) at 4°C overnight.
The number of capillaries was counted in regions with
transversely sectioned myocytes in the border zone. Five
fields per section were randomly selected and analyzed.
Twenty sections per heart were blindly evaluated to
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estimate capillarity. The number of capillaries was
assessed from photomicrographs using a computerized
image analysis system (Image Pro Plus 4.0, Media Cyber-
netics. L. P., USA).
Detection of myocardial perfusion
At day 28 after transfection, the myocardial infarction-
induced dogs treated with HGF were reanesthetized and
their chests were opened. Approximately 700,000 radio-
active microspheres (NEN Life Science Product, Inc.,
Boston, MA, USA) labeled with 51Cr were injected into
the left ventricular cavity [21]. The microspheres were
allowed to circulate for 1 min. The animals were then
euthanized and their hearts were excised. Tissue speci-
mens from the left ventricle, including the septum and
right ventricular free wall, were excised for measure-
ment of radioactivity. The activities in the left ventricle
were expressed per weight of heart tissue as a ratio rela-
tive to the activity in the right ventricular free wall [21].
Statistical analysis
Data are expressed as mean ± standard deviation (sd).
Analysis of variance (SPSS 14.0 Statistical Software,
SPSS, Inc., Chicago, IL, USA) was used to assess the
capillary density, protein expression, and EGFP and
HGF mRNA levels. Viability comparisons across multi-
ple experimental groups were conducted using a one-
way analysis of variance (ANOVA) followed by post-hoc
Tukey analysis to determine significant differences. P <
0.05 was considered to be statistically significant.
Results
A total of 40 animals were subjected to coronary artery
ligation; none of the animals died during the operation.
38 (95%) survived and were included in the experiments.
Although two dogs died at during 24 hour after the
treatments, no dogs died subsequently until the final
evaluation at four weeks. The dogs with measured
infarct sizes less than 20% of LV circumference were
excluded from the study (one dog in MI group, one dog
in HGF-US/MB group).
Gross pathology
No acute pericardial tamponade or episodes of sustained
ventricular arrhythmia were noticed after intramyocardial
injection of microbubbles and a gene in the animals. The
pericardial sac was examined, and pericardial effusion
and hematoma were not observed. Harvested hearts had
no intramyocardial hematoma, splits, or perforations.
CK secretion
As shown in Table 1, there was no significant difference
in CK secretion among the four EGFP groups (i.e.,
among measurements taken before the experiment,
during the operation, at the end of the experiment, and
at 24 and 48 h after transfection).
Microbubble imaging characterization
Long-axis images confirmed the presence of microbubbles
and the gene at the injection sites, as seen in ultrasound
images acquired in real time (Figures 1a, 1b, 1c, 1d, 1e, 1f,
1g, 1h). The distribution and the sizes of the microbubble
mixture in the myocardium were clearly observed once
injection was completed. The microbubble-enhanced ima-
ging regions were mainly confined to approximately one
half of the myocardial thickness (Figure 1b). Clear imaging
of intramyocardial injection of 0.1 ml diluted micro-
bubbles at a concentration of 1.42 ± 0.26 ×109/ml was
possible.
Area of the microbubble-enhanced imaging regions
The extent of intramyocardial microbubble-enhanced
imaging (maximal depth and width) was measured to
identify local diffusion of the microbubble tracer at the
injection site. The imaging sizes of the mixture of micro-
bubbles and the EGFP gene in regional myocardium was
measured in three dogs using a Sonos 4500 ultrasound
system. When the needle was extended 6 mm into the
myocardium and the injection volume of microbubbles
and the gene was 0.1 ml, the imaging size was 3.2 ±
1.0 mm in depth and 7.6 ± 1.9 mm in maximal width at
the moment of injection. The imaging realm was 1.8 ±
0.6 mm in depth and 4.3 ± 1.1 mm in maximal width
after 60 min. The area of the contrast-enhanced region of
0.1 ml microbubbles and the gene decreased from 24 ± 2
mm2 initially to 10 ± 1 mm2 after 60 min (P < 0.05)
Imaging persistence of microbubbles
Visualization of microbubbles and the gene at the injection
site was distinct. The image intensity gradually decreased
in the myocardium. The gray-scale intensity of the micro-
bubble-enhanced regions changed slowly and slightly
within 30 min, and then the intensity gradually decreased.
The image intensity and extent faded by about 60-70%
after 60 min (Figure 1h), but the microbubble-enhanced
imaging regions in the myocardium of the left ventricle
free wall were still visible at this time (Figure 1h).
Table 1 Analysis of the serum CK activity in the four
groups (x ± sd, n = 4)
CK(U/L) EGFP+MB/
US
EGFP
+US
EGFP
+MB
EGFP
alone
Experiment before 269 ± 59 284 ± 62 279 ± 64 258 ± 56
During the operation 271 ± 61 291 ± 66 281 ± 70 261 ± 55
End of the
experiment
278 ± 60 288 ± 60 284 ± 63 268 ± 61
24 h 264 ± 58 282 ± 62 277 ± 61 267 ± 59
48 h 268 ± 54 279 ± 59 275 ± 60 253 ± 57
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Detection of EGFP mRNA expression
RT-PCR data revealed expression of EGFP mRNA in all
groups (Figure 2a). EGFP was expressed at low levels in
the EGFP group, and no statistical differences in EGFP
expression were detected between the EGFP+MB group
and the EGFP group. The EGFP mRNA expression of
the EGFP+MB/US group was about 14.7 times higher (P
< 0.01) and the EGFP+US group was about 5.6 times
higher (P < 0.01) than that of the EGFP alone group
(Figure 2b).
Detection of EGFP protein expression
Confocal laser scanning fluorescence microscopy
revealed that green fluorescence was observed through-
out the myocardial cells around the injection region in
the EGFP+MB/US group after 48 h (Figures 3a, 3b, 3c).
As shown in Figure 3d, the EGFP fluorescence intensity
of the EGFP+MB/US group was about 11.6 times higher
(P < 0.01) and that of the EGFP +US group was about
3.9 times higher (P < 0.01) than that of the EGFP alone
group. In the EGFP alone group, weak green fluores-
cence could be seen in scattered cells within the myo-
cardium, and its intensity was obviously lower than that
in the EGFP+MB/US group and the EGFP+US group.
There was no significant difference in green fluores-
cence between the EGFP+MB and the EGFP groups
(P > 0.05).
Human HGF gene expression in ischemic myocardial
muscles
ELISA data showed that the HGF content in the myo-
cardium was the highest in the HGF+MB/US group
(Figure 4) (P < 0.01). There was no significant difference
between the HGF+MB and the HGF groups (P > 0.05).

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Figure 1 Imaging of the microbubbles at the intramyocardial injection site. EGFP plasmid DNA (100 μg) was mixed with 0.1 ml of
microbubble solution and injected into the myocardium of the left ventricle anterior wall. (a) Long-axis view before contrast injections. (b) The
same long-axis view showing contrast injection at 5 min (indicated by the white arrow); the contrast is visible as the hyperintense signal
indicated by the white arrow. (c) Long-axis view showing contrast injection at 10 min. (d) Long-axis view showing contrast injection at 20 min.
(e) Long-axis view showing contrast injection at 30 min. (f) Long-axis view showing contrast injection at 40 min. (g) Long-axis view showing
contrast injection at 50 min.(h) Long-axis view showing contrast injection at 60 min.
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Capillary density
CD31 antibody was used to detect capillaries at day 28
post transfection in the HGF-treated dogs. Immunohis-
tochemistry results showed that CD31 expression
appeared as brown granules, which were located on the
membrane and endochylema of vascular endothelial
cells. The capillary density in the HGF+MB/US group
was the greatest (Figure 5). The increased capillary den-
sity was mainly limited to the area around the infarct
area (border zone). Capillary densities of the HGF+MB/
US group (146.7 ± 31.4/mm2) and the HGF+US group
(62.5 ± 16.4/mm2) were significantly higher (P < 0.01)
than that of the HGF+MB group (42.6 ± 11.9/mm2), the
HGF group (41.9 ± 10.5/mm2), and the control group
(20.8 ± 3.4/mm2). The capillary density was (78.7 ±
23.4/mm2) in the MB/US group. There was no signifi-
cant difference in the capillary density between the HGF
+MB and the HGF groups (P > 0.05).
Measurement of regional blood flow
Radioactive microspheres were used to measure relative
blood flow. The right ventricular free wall served as the
reference region. The average weights of the left ventri-
cle and the right ventricular free wall in each heart were
77.6 g and 12.9 g, respectively. The regional blood flow
ratio was significantly higher in the HGF-treated dogs
than in the control group (Figure 6). The regional blood
flow ratio was highest in the HGF+MB/US group.
Discussion
Previous animal studies have proven the feasibility of
enhancing collateral function by delivery of angiogenic
factors to the myocardium [1,2,22-24]. Intramyocardial
gene transfer allows nonviral vector delivery directly to
the target area. Plasmid delivery methods are relatively
safer, but their transfection efficiencies are low even
after direct injection. Recently, researchers have begun
 EGFP 401bp 
Marker     1       2       3       4 
(A) ˟-actin 540bp
(B)
Figure 2 EGFP mRNA expression in injection regions of the
myocardium for four different treatment groups, as evaluated
using RT-PCR technology. (x ± sd, n = 4). (a)M: marker; 1 lane:
EGFP group; 2 lane: EGFP + US group; 3 lane: EGFP +MB/US group;
4 lane: EGFP +MB group. (b) *P < 0.01 vs. EGFP group and EGFP+
MB group; **P < 0.01 vs. other three groups. # P > 0.05 vs. the EGFP
group. b-actin was used as the internal control.
a Cb
d
Figure 3 EGFP protein expression in injection regions of the
myocardium for four different treatment groups, as evaluated
using confocal laser scanning microscopy. (Scale bar = 50 μm).
(a) Expression of EGFP in the myocardium of the EGFP+MB/US
group (original magnification ×400). (b) Expression of EGFP in the
myocardium of the EGFP+US group (original magnification ×400).
(c) Expression of EGFP in the myocardium of the EGFP group
(original magnification ×400). (d) (x ± sd, n = 4). *P < 0.01 vs. the
other three groups; **P < 0.01 vs. the EGFP group and the EGFP
+MB group; # P > 0.05 vs. the EGFP group.
Figure 4 Analysis of HGF content in the myocardium as
measured by ELISA for four different treatment groups. HGF
protein expression was assessed at day 28 after transfection (x ± sd,
n = 6). *P < 0.01 vs. other five groups; **P < 0.01 vs. HGF +MB
group and HGF alone group; # P > 0.05 vs. HGF alone group.
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to use microbubble contrast agents as a diagnostic ima-
ging tool and as a gene carrier [11-14]. Some studies
have shown that ultrasound, used either alone or in
combination with microbubbles, can delivery of genes to
specific tissues, including the myocardium and increase
gene expression [25-28].
Systemic administration of HGF by ultrasound-tar-
geted microbubble destruction for therapeutic angiogen-
esis has been demonstrated to be effective [3-6]. More,
US/MB has been used to enhance the delivery of HGF
into the skeletal muscle by direct intramuscular
injection of a naked plasmid into the rat hind limbs
[27]. This technique was applied to the heart, and the
successful cardiac delivery of a reporter gene was
achieved by using an adenovirus vector loaded on MBs
[25]. However, for the therapeutic use in patients, inno-
vations in non-viral plasmid DNA-based gene transfer
with high transfection efficiency would be desirable [11].
In this study, when US/MB was combined, naked HGF
plasmid injected into the blood circulation, not the
direct injection or intracoronary injection, was success-
fully transferred into the myocardium. These results
ba c
d e
f
Figure 5 Immunohistochemistry results of CD31 expression in five different treatment groups. The number of blood vessels in transverse
sections of the dog ischemic myocardium harvested at day 28.(Scale bar = 20 μm). (a) Expression of CD31 in the HGF+MB/US group (original
magnification ×400). (b) Expression of CD31 in the MB/US group (original magnification ×400). (c) Expression of CD31 in the HGF+US group
(original magnification ×400). (d) Expression of CD31 in the HGF group (original magnification ×400). (e) Capillaries in the control group. (f) The
capillary density of HGF+MB/US group was the highest among all groups (x ± sd, n = 6). *P < 0.01 vs. other five groups; **P < 0.01 vs. HGF +US
group, HGF alone and HGF +MB group; *** P < 0.01 vs. HGF alone and HGF +MB group; # P > 0.05 vs. HGF alone group.
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provide the basis for the application of US/MB for non-
viral transfection of therapeutic genes into the myocar-
dium by systemic administration of the naked plasmid
[13-15]. However, the naked plasmid injected into the
blood is easily degraded by DNase or captured by non-
specific scavenger receptors [11,29], which leads to rapid
decrease in concentration of the plasmid reaching the
target regions. Thus a high dose of the plasmid could be
needed for intravenous injection to achieve the similar
plasmid concentration obtainable with intramyocardial
injection [11]. Therefore, further studies are necessary
to optimize the insonation condition in the specific tar-
get organs with various acoustic properties in larger ani-
mals [11].
Therefore, we chose to inject the plasmid into the
myocardium rather than the peripheral vein or the LV
chamber. In our study, we found that the combined
therapy of direct intramyocardial injection of low-dose
of HGF/MB and insonation induced more gene expres-
sion and capillary formation than either therapy alone.
We analyze the reason as following: (1) Ultrasound can
produce a variety of nonthermal bioeffects via acoustic
cavitation and enhance the biological effects of micro-
bubbles in the regional myocardium. The plasmids can
take advantage of increased cell and capillary permeabil-
ity after ultrasound-targeted microbubble destruction
[11-14]. Thereby facilitating HGF DNA transfer through
both artificial and biological membranes and enter
cells in deeper layers [11-16]; thus a combination of
approaches (direct administration of HGF and micro-
bubbles into the myocardium and the use of US)
resulted in high HGF expression in the HGF+MB/US
group. The higher expression of HGF in the regional
myocardium facilitates dramatic capillary growth. (2)
Some studies have shown that ultrasonic destruction of
microbubbles in the microcirculation causes local
inflammatory cell infiltration, therefore inducing angio-
genesis [30,31]. In our study, the ultrasonic destruction
of microbubbles in the regional myocardium also direct
induced angiogenesis.
As we mentioned before, invisible intramyocardial
delivery could be dangerous in vivo, especially because
myocardium cells may be replaced by scar tissue after
myocardial infarction, and thus delivery of the gene
could result in pericardial effusion or other injuries [32].
Evaluating the injection depth and breadth is critical for
intramyocardial injection. Our study has shown that
direct intramyocardial injection of microbubbles and a
gene presents advantages for direct visualization. The
microbubble-enhanced ultrasound imaging improves
delineation of the injection border in the regional myo-
cardium, which helps in estimating injection depth and
radius in the ventricular wall. Moreover, left ventricular
perforation and the intramyocardial injection of proce-
dure can be monitored using echocardiography. This
offers the potential advantage of accurately guiding
transcatheter-targeted intramyocardial delivery of thera-
peutic agents.
The microbubble-enhanced imaging regions in the
myocardium can be observed for 60 min. This long-last-
ing imaging time provides a good opportunity to
observe the trace of the cell or gene mixed with micro-
bubbles in the myocardium. Thus, intramyocardial injec-
tion of an extracellular microbubble contrast medium
may be useful as a marker for observing the distribution
of intramyocardial-delivered therapeutic agents.
Moreover, ultrasound can be focused and therefore
targeted toward specific and, if necessary, deep locations
within the body. If the biologic and clinical importance
of angiogenic treatment is ultimately demonstrated, the
method we describe in this report may constitute an
important new strategy for treating patients with myo-
cardial ischemic syndromes.
Conclusions
In sum, systemic administration method need a high
dose of gene and microbubble and induce side effect of
non-target organ delivery. Direct intramyocardial injec-
tion of a mixture of a low-dose of an angiogenic gene
with microbubbles followed by insonation treatment can
enhance gene expression and angiogenesis. Microbub-
bles can also be used as a marker for observing the
trace of the gene mixed with microbubbles in the myo-
cardium, thus significantly increasing the safety of the
intramyocardial injection procedure.
Study limitations
Further investigations are needed to optimize this inter-
esting, visible, effective, and novel gene delivery method.
Figure 6 Effect of intramyocardial injection of HGF/microbubbles
combined with ultrasound on regional myocardial blood flow.
(x ± sd, n = 6). The radioactivities in the left ventricle were
expressed per weight of heart tissue as a ratio relative to the
activity in the right ventricular free wall. *P < 0.01 vs. other five
groups; **P < 0.01 vs. HGF +US group, HGF alone and HGF +MB
group; ***P < 0.01 vs. HGF alone and HGF +MB group; # P > 0.05
vs. HGF alone group.
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The gene expression pattern of EGFP and HGF were
not tested in this study in order to reduce the number
of dogs used. The efficiency of gene transfection by US/
MB should be dependent upon insonation conditions as
well as MBs structure. Therefore, further studies are
necessary to optimize the insonation condition, and
future studies should pursue the tradeoff between the
efficacy and safety in respect to MB concentration and
US intensity.
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